• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail
?
-

Resources for You

Isentress (raltegravir potassium) tablets

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) -- July 2009

 

Summary View

 

ADVERSE REACTIONS

Postmarketing Experience

  • addition of paranoia and anxiety

DRUG INTERACTIONS

  • warning about use with UGT (UDP-glucuronosyltransferases) inducers other than rifampin, specifically, Coadministration of Isentress with drugs that are strong inducers of UGT1A1 may result in reduced plasma concentrations of raltegravir